Two Policies, One Moment: The White House Says Test Strips Work — Then Blocks the Money to Buy Them

When the White House published its 2026 National Drug Control Strategy this month, it described fentanyl test strips in plain terms: “an important tool that should be legal and not considered drug paraphernalia.” Three weeks earlier, HHS directed SAMHSA to prohibit federal funding from purchasing them. Both positions came from the same administration. Neither has been retracted.

This is not a technicality. It is the central tension defining overdose prevention policy in America right now — and the gap between these two documents will determine whether community organizations on the front lines of the fentanyl crisis can keep doing the work that has driven a meaningful drop in overdose deaths.

What the Strategy Says — and What HHS Did

The ONDCP’s 2026 strategy is notable for what it avoids as much as what it endorses. The document does not use the phrase “harm reduction,” a politically freighted term the current administration has largely abandoned. But it does describe a set of practices that are, functionally, harm reduction: naloxone distribution and training, overdose response as “the beginning of recovery,” national wastewater drug surveillance, and drug identification technology that helps people know what is in their supply.

Among those tools: fentanyl test strips.

Test strips are small, inexpensive devices that detect the presence of fentanyl in a drug sample before it is consumed. Evidence compiled by the CDC and independent researchers consistently shows that people who use drugs and have access to test strips are significantly more likely to take protective actions — using less, using with a witness present, carrying naloxone — when a positive result appears.

On April 24, SAMHSA issued updated guidance to grantees specifying which supplies may and may not receive federal funding. The prohibited list includes fentanyl test strips and “substance adulterant detection kits.” Also prohibited: syringes, needles, sterile water, saline, and ascorbic acid for drug preparation. Permitted: naloxone, wound care, FDA-approved HIV home testing, condom distribution, nicotine cessation.

The practical effect is that organizations receiving federal SAMHSA grants — a category that includes most community health organizations, syringe service programs, and harm reduction nonprofits operating at scale — can no longer use those dollars to buy test strips for the people they serve.

A 27% Drop in Deaths, at Risk

The stakes are not abstract. Provisional CDC data reported by the Drug Policy Alliance shows that overdose deaths declined approximately 27% in 2024 compared to 2023. After years of relentlessly rising mortality, that is a genuine public health achievement. Researchers credit multiple factors: increased naloxone availability, expanded buprenorphine prescribing, and — critically — the widespread deployment of fentanyl test strips that helped people in the drug supply make informed decisions about risk.

The current policy environment compresses every component of that achievement simultaneously. Medicaid, which funds roughly one-quarter of all U.S. substance use disorder treatment, faces a 15% cut under H.R. 1 (the “One Big Beautiful Bill Act”). SAMHSA’s FY2026 budget is cut by the same percentage. Federal harm-reduction grants, briefly terminated in January 2026 before being restored after bipartisan pushback, remain precarious.

The Legal Complexity on the Ground

The conflict between the ONDCP strategy and SAMHSA’s guidance is not simply an embarrassment for the administration. It creates genuine legal uncertainty for the people running programs.

Faces & Voices of Recovery’s May 2026 policy update notes that 45 states retain active CDC-authorized agreements that permit syringe purchases when necessary to control a hepatitis or HIV outbreak — a carve-out written into FY2026 appropriations language. The SAMHSA guidance adds new restrictions on top of this. Whether state-level CDC agreements override SAMHSA guidance, and under what conditions, is not currently settled.

Whether state-level CDC agreements override SAMHSA guidance, and under what conditions, is not currently settled.

The ONDCP strategy, meanwhile, carries its own weight as an official White House policy document — one signed by senior administration officials. A grantee in Phoenix who reads the strategy and uses federal funds to buy test strips, relying on the White House’s own words, may still be in technical violation of the SAMHSA guidance. That is not a tenable position for an organization whose funding depends on federal compliance.

What This Means for Recovery Navigation

For people actively using drugs — or for people who love someone who is — the confusion at the federal level translates into real gaps in what is available at the community level.

Test strips are most useful at the moment of risk: before someone uses a substance of uncertain composition. That is precisely the moment when a connection to a harm reduction program, and through it to treatment options, is most possible. Programs that distribute strips frequently serve as the first point of contact between people in active use and the broader recovery system — the place where someone might, for the first time, be asked what they want their life to look like.

Cutting access to that infrastructure does not reduce drug use. It removes the safety net that keeps people alive long enough to reach it.

Why This Matters for People in Recovery

If you are in recovery, or supporting someone who is, understanding the policy environment is not abstract civics. The organizations that helped you or your loved one get connected to treatment — the harm reduction programs, the community health workers, the peer navigators — depend on federal funding that is currently under pressure from multiple directions.

The gains of the past two years are not locked in. They are the product of a system of interventions that requires ongoing support to function. The 27% decline in overdose deaths is a number worth fighting to protect.

If you or someone you know is looking for treatment, Rize Recovery’s free matching tool connects you with facilities that accept your insurance and match your specific needs — regardless of what is happening in Washington. Start here.

For real-time policy tracking on harm reduction funding, Faces & Voices of Recovery maintains monthly policy updates at facesandvoicesofrecovery.org.